IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment
Targeting IDO1 represents a promising strategy to overcome immunosuppressive barriers in gastrointestinal cancers, improving the efficacy of CLDN18.2-CAR-T therapy. These findings highlight the potential for integrating IDO1 inhibition into CAR-T treatment regimens to address resistance in treatment-refractory cancers.
Authors
- Changmian Ji (ORCID: https://orcid.org/0000-0001-8781-4063)
- Hongye Wang (ORCID: https://orcid.org/0000-0002-6467-0316)
- Yan Lin (ORCID: https://orcid.org/0000-0002-7055-3183)
- Haigang Geng (ORCID: https://orcid.org/0009-0009-5765-5992)
- Bo Zhai (ORCID: https://orcid.org/0000-0003-4337-7126)
- Yanmin Zhang (ORCID: https://orcid.org/0000-0001-7307-9408)
- Zhigang Zheng (ORCID: https://orcid.org/0000-0002-6440-6398)
- Zhaorong Wu (ORCID: https://orcid.org/0000-0003-1897-1721)
- Xiaorong Huang (ORCID: https://orcid.org/0000-0003-0379-5972)
- Hongshu Jing
- Jiufei Zhu
- Linke Bian
Institutions
- Fujian Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Shanghai Cancer Institute (CN)
- Fuzhou Pulmonary Hospital of Fujian (CN)
- Shanghai East Hospital (CN)
- State Key Laboratory of Oncogene and Related Genes (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-03-05
- DOI
- https://doi.org/10.1186/s12967-025-06276-x
- Citations
- 17
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 17.77
Funders
- National Science Foundation